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Eosinophils  are  a  major  component  of the  host-immune  response  to  helminth 
infections  (1,  2),  and  factors  modulating  their  helminthotoxic  capacity  are  now 
receiving  considerable  attention.  Lymphokines  secreted  by  cells  form  Schistosoma 
mansoni  egg granulomas  (3)  and eosinophil chemotactic factor of anaphylaxis tetra- 
peptides released by mast cells  (4-6)  potentiate the ability of eosinophils to destroy 
helminths in vitro;  the release of these  factors in vivo probably results in the local 
activation of tissue eosinophils. 
Recent  studies  suggest  that  circulating  eosinophils  isolated  from  the  blood  of 
eosinophilic  patients  are  activated:  they  have a  low surface charge,  high  levels of 
certain lysosomal and membrane enzymatic activities (7),  and enhanced helmintho- 
toxicity in vitro (8).  Also, blood eosinophils in eosinophilic patients are often vacuo- 
lated  and  degranulated  (9-11),  and  certain  substances  normally  stored  in  their 
granules have been found in abnormal concentrations in the blood of some of these 
patients  (12,  13).  It has been suggested that these cells, unlike eosinophils in normal 
individuals, release their granule content in the blood in response to unknown stimuli. 
Some of these eosinophil-derived substances are toxic for mammalian cells  (14,  15), 
and they could be responsible for the tissue damage observed in some patients with 
hypereosinophilic syndrome (12,  16-18). 
The mechanisms causing these changes in the properties of blood eosinophils are 
not  known.  Because  they occur  in  association  with  eosinophilia,  it  is  possible that 
some  eosinopoietic  factors  induce  them.  Colony-stimulating  factors  (CSF) 1 could 
probably  have  this  dual  function  because  they  have  been  reported  to  stimulate 
progenitor cells (19)  as well as mature cells (20-22). 
We tested this hypothesis using a  human placental conditioned  medium that is a 
source of human eosinophil CSF (23,  24). The data show that a material contained in 
the human placental conditioned medium markedly enhances eosinophil cytotoxicity. 
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This material copurifies with eosinophil CSF on phenylsepharose and Sephadex G- 
100 columns, suggesting that eosinophil CSF might be the molecule(s) responsible for 
the  enhancement of eosinophil cytotoxicity.  Studies on  the  mechanism of this  en- 
hancement suggest that normal blood eosinophils develop, after a short time incuba- 
tion with this factor(s), properties that resemble some of the properties presented by 
circulating eosinophils in hypereosinophilic patients. 
Materials and Methods 
Life  Cycle of S.  mansoni.  A Puerto Rican strain of S.  mansoni  was routinely maintained by 
passage through outbred mice and Biomphalaria  glabrata  snails. Schistosomula were prepared by 
allowing cercariae to penetrate an isolated preparation of rat skin in vitro (25, 26). 
Antisera.  Sera from patients with S. mansoni infection, either single or in pools, were used as 
a source of antischistosomular antibodies. All sera were heat-inactivated at 56°C for 1 h and 
had previously been tested for their ability to mediate microscopically detectable eosinophil- 
dependent damage to schistosomula in vitro. 
Effector Cells.  Neutrophils and eosinophils were recovered from the blood of normal individ- 
uals by fractionation on metrizamide gradients as previously described (27). Cytocentrifuge 
smears of different cell fractions were stained with Wrights Giemsa for immediate examination, 
and fractions were  pooled as  appropriate.  Purity of cell  preparation is  indicated in figure 
legends; in the case  of eosinophils, the contaminating cells were neutrophils; in the case  of 
neutrophils, the contaminating  cells were mononuclear cells with occasional eosinophils. Cells 
and schistosomula were washed and resuspended in minimal essential Eagle's medium supple- 
mented with 25 mM of Hepes, 100 U/ml penicillin G, 100 ~tg/ml streptomycin, 1% glutamine, 
10% fetal calf serum (FCS),  and 30 mg/liter deoxyribonuclease, as previously described (27) 
(MEM/FCS/D). Cell concentratiohs were adjusted to 2 or 8 ×  108 cells/ml, yielding effector 
cell-to-target schistosomulum ratios  of  1,000:1 (adherence assay)  or  4,000:1  (killing assay). 
Because  neutrophils also adhere to antibody (AB)-coated schistosomula, the eosinophil adher- 
ence assays were performed with eosinophils that were >98% pure. 
Adherence  Assay.  Aliquots containing 100  schistosomula (50 bd), eosinophils (50 /11), and 
appropriate  dilutions of antischistosomular antiserum  (50  p.l) and  a  fraction of placental 
conditioned medium (50/zl) were incubated for 1-6 h in humidified airtight boxes at 37°C. At 
the end of the incubation period, schistosomula and cells that had sedimented at the bottom of 
the tubes were gently resuspended in 50 #1 of assay medium and placed on a slide previously 
coated with 2 drops of 0.1% toluidine blue in methanol. The number of adherent cells on each 
organism was  then  counted at  a  magnification of  100×.  In most  experiments, results  are 
recorded as the percentage of schistosomula bearing >20 cells. This threshold of 20 cells per 
schistosomula was chosen because it corresponds usually to the degree of eosinophil adherence 
required to kill the schistosomula when incubation is prolonged up to 24 h for the killing assay. 
Coneanavalin A (Con A)-dependent eosinophil adherence is weaker than antibody-dependent 
eosinophil adherence at  37°C  (28).  Therefore, Con A-dependent eosinophil adherence was 
recorded as the percentage of parasites bearing >10 cells. 
Killing  Assay.  100 schistosomula, 4  ×  105 eosinophils, and appropriate dilutions of anti- 
schistosomular antiserum and placental conditioned medium were incubated in plastic tubes as 
indicated for the adherence assay. Damage was determined after 24 h of culture. Larvae were 
scored  as  dead  if they were  immotile and had  taken up  toluidine blue in an  intense and 
granular fashion (27). Separate experiments have shown that schistosomula considered dead by 
these criteria are unable to mature into adult worms when reinjected into mice.  2 
Inhibition  of Eosinophil Protein Synthesis  by Puromycin.  Eosinophils (93% pure) were resuspended 
(8 ×  108 cells/ml) in methionine-free  Dulbecco's medium supplemented with 20 mM Hepes, 20 
mM glutamine, 100 U/ml penicillin, 100/.tg/ml streptomycin, and 0.01 mM [35S]methionine 
(sp act, 1,000 Ci/mmole) with or without 5 pg/ml puromycin (63178; Sigma Chemical Co., St. 
Louis, MO). After 3 h incubation, 10  s cells were deposited on a filter paper (Whatman, 3 mM) 
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that was immediately immersed in 10% boiling trichloroacetic acid; the cells on the filters were 
then  washed  three  times  in  10%  trichloracetic  acid  and  twice  in  90%  ethanol,  dried,  and 
counted. 3SS incorporation (106 cells) was as follows: cells incubated without puromycin, 63,000 
+  5,000  cpm; cells  incubated with  puromycin, 22,000  +  3,000  cpm; and cells  kept  at  4°C, 
25,000 +  4,000 cpm. 
Preparation of Conditioned Media.  Human  placental  conditioned  medium  was  prepared  as 
described previously (24).  Briefly,  pieces  of fresh human placenta were incubated for 7 d  in 
RPMI  1640 medium containing 5% FCS. The supernatant  was then collected,  pooled, and 
tested for CSF activity. 
Purification of CSF  from Human Placental Conditioned  Medium (HPCM) 
GEL FXLTRATXON  ON SEPHAr)EX  C-100.  HPCM was concentrated 10-fold using an Amicon DC- 
2A apparatus (Amicon Corp., Scientific Sys. Div., Lexington, MA) with a H 1P 10 hollow filter 
cartridge and dialyzed against distilled water. It was then absorbed to calcium phosphate gel 
and eluted with 0.05 M sodium phosphate buffer as described previously (29). This concentrated 
material  (25  ml)  was  then  applied  to a  column  of Sephadex  G-100  (29) (LKB-Produkter, 
Bromme, Sweden), 2.6 X 100 cm, and eluted at a flow rate of 15 ml/h with phosphate-buffered 
(0.02  M,  pH  7.3) saline  (0.15  M)  containing  polyethylene  glycol 6,000  (0.005%  wt/vol). 
Fractions of 5 ml were collected and assayed separately before pooling. 
FRACTIONATION  ON PHENYL SEPHAROSE  CL-4B.  Samples of HPCM (either calcium phosphate 
eluates or active fractions from gel filtration) were applied to a column ofphenyl sepharose CL- 
4B,  2.6  X 20 cm, (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated  in phosphate- 
buffered  saline  (29).  The column was eluted  with  the same buffer until  eluate  absorbance 
reached background level, and then the eluate was changed to 60% (vol/vol) ethylene glycol in 
distilled  water.  CSF failing to bind to the resin  in phosphate-buffered saline was designated 
fraction-a, and that eluting with ethylene glycol was designated fraction-ft. 
Results 
Enhancement by HPCM of the Antibody-dependent EosinophiLmediated Killing of Schistosom- 
ula.  Schistosomula were incubated  with purified  human blood eosinophils with or 
without  HPCM  and  human  antischistosomular  serum.  In  the  presence  of HPCM 
there was a  4- to  10-fold increase in parasite death scored after 20 h  of culture. This 
enhancement of eosinophil cytotoxicity was observed with eosinophils from the blood 
of all  15  volunteers  tested  (eosinophil  count  between  1 and  15%)  and  with  all  10 
human antischistosomular sera assayed. Table I shows the details of such experiments 
performed  with  eosinophils  from  the  blood  of five  different  individuals.  HPCM 
without eosinophils was not toxic to the larvae;  it should be noted, however, that  it 
allowed a modest antibody-independent eosinophil-mediated killing of schistosomula. 
Neutrophils  adhered to antibody-coated larvae but  failed to damage them  in our 
assay (27). HPCM  did not stimulate neutrophils to kill the larvae (Table I). 
Enhancement of eosinophil cytotoxicity was maximum at antibody concentrations 
that  allowed  a  marginal  killing  of schistosomula  by  control  eosinophils  (Fig.  1). 
Moreover, in the presence ofHPCM, eosinophils required 5 to 10 times less antibodies 
than control eosinophils to demonstrate a similar killing ability (Fig. 2). 
Enhancement of eosinophil cytotoxicity was proportionate to the dilution of HPCM 
(Fig.  2).  This effect was observed at  dilutions  of up  to  1/500.  Small  but  significant 
enhancement  of  the  antibody-independent  eosinophil  killing  of schistosomula  is 
observed in most experiments at dilutions up to  1/100. 
Enhancement by HPCM of the Complement-dependent Eosinophil-mediated Killing of Schisto- 
somula.  Purified  human  eosinophils kill schistosomula coated with  human  comple- 
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TABLE  I 
Enhancement by HPCM of the Ab-dependent Eosinophil-mediated Damage to Schistosomula 
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Percent dead schistosomula 
Neutrophils 
Patient  HPCM  Ab  Eosinophils +  Ab  +  Ab 
Y4o*  1/4o  lmo  0%  % 
1  -  4  ±  2  (A)§  14 ±  2  NDI]  3  ±  1  ND 
+  3 :t: 3  62 +  5¶  ND  14 +  2¶  ND 
2  -  2±2(B)  70±  12  30+2  3±2  ND 
+  3 :t: 4  98 ±  2¶  85 ±  2¶  20 ±  2¶  ND 
3  -  7±4  (C)  20±3  5±2  7±3  8±4 
+  7±3  85±  10¶  48±4¶  13+  5  10±5 
4  -  5+3((2)  12±5  4±2  5±2  9±3 
+  6±4  90±2¶  38±  10¶  7±4  8±4 
5  -  3±3(A)  21 ±4  6±3  1±  1  6±4 
+  4±  1  79±4¶  49±5¶  10~4  9+3 
Eosinophils and neutrophils were purified (>90% pure) from the blood of five different patients (blood 
eosinophil count  1-8%), and their ability to kill schistosomula in the presence of antischistosomular Ab 
was tested as described  in Materials  and Methods.  HPCM  (IA(~) was added  at  the beginning of the 
culture. Numbers represent arithmetic means of duplicate determinations ±  SD obtained in five separate 
experiments (one experiment for each patient). 
* Dilutions of human antischistosomular antiserum. 
:[: No antibody. 
§ Letters in parentheses refer to the human antischistosomular  serum used in the corresponding experiment. 
][ Not determined. 
¶ Values that differ significantly from their controls (incubations without HPCM) P <  0.01. 
prepared schistosomula; skin-prepared schistosomula are much less susceptible (32). 
HPCM caused a 4- to 10-fold enhancement of the complement-dependent eosinophil- 
mediated killing of skin-prepared schistosomula. Eosinophils incubated with HPCM 
killed schistosomula at fresh normal human serum concentrations that were 5 to  10 
times lower than those required by control eosinophils (Fig. 3). 
Copurification of Eosinophil Cytotoxicity Enhancing Activity with Eosinophil Colony-stimulat- 
ing  Activity (CSA).  Chromatography  on  phenyl-Sepharose  columns  resolves  the 
HPCM  into  two major  fractions, a  and fl  (29).  Both  fractions have  granulocyte- 
macrophage-CSA, but only fraction-a has eosinophil CSA; when tested in the killing 
assay, only fraction-a enhanced the antibody-dependent eosinophil-mediated killing 
of schistosomula (Table II). As was found with unfractionated HPCM,  fractions a 
and fl were unable to convert antibody-dependent neutrophil adherence to schisto- 
somula into a killing reaction. 
It was also found that  eosinophil cytotoxicity-enhancing activity and eosinophil 
colony-stimulating activity are associated with molecule(s) having a similar apparent 
molecular weight (~30,000). The HPCM was filtered on Sephadex G-100  (29),  and 
eosinophil CSA-containing fractions were pooled and tested in the killing assay (Table 
II).  These  fractions  enhanced  antibody-dependent  eosinophil-mediated  killing  of 94  IN VITRO ACTIVATION OF HUMAN BLOOD EOSINOPHILS 
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Flc.  1.  (left) Enhancement by HPCM of the Ab-dependent eosinophil-mediated  killing of schis- 
tosomula at various Ab concentrations. Schistosomula  were incubated with eosinophils  (>89% pure 
from donors with  blood eosinophil counts of  3-13%) and  grading  concentrations of human 
antischistosomular antisera. HPCM  (1/100) was added to the culture at the  beginning of the 
incubation period. Each point represents the arithmetic mean ±  SD of determination in three 
separate experiments. 
Fro.  2.  (right) Enhancement by  HPCM  of the  Ab-dependent eosinophil-mediated killing of 
schistosomula at  various HPCM concentrations. Sehistosomula were incubated with eosinophils 
(>85% pure from donors with blood eosinophil  counts of 4-10%). HPCM was added to the culture 
at  the beginning of the incubation period. To reveal a maximum HPCM-mediated enhancing 
effect, antischistosomular sera (from three different patients) were used at  dilutions that  corre- 
sponded to the thresholds that  permit eosinophil-mediated killing of schistosomula. Each point 
represents the mean ±  SD of duplicate determinations of the percentage of dead schistosomula 
observed in three separate experiments. 
schistosomula. They did not allow neutrophils to  damage Ab-coated larvae  (Table 
TT). 
All subsequent experiments were performed with the G-100 and phenyl-Sepharose- 
purified fraction of HPCM. This fraction will be referred to as CSF-a. 
Effect of CSF-a on Eosinophil Adherence to Schistosomula.  The next experiments were 
carried  out  to  investigate the  mechanism  of the  enhancement of  the  eosinophil- 
mediated  killing of schistosomula by  CSF-a.  It  was  found  that  CSF-a  enhances 
eosinophil adherence to antibody-coated schistosomula (Fig. 4).  This enhancement 
was  observable 90  min after  the  addition of CSF-a  to  the  culture.  At  that  time, 
eosinophils incubated with  CSF-a  adhered  to  the  larvae  twice  as  well  as  control 
eosinophils. Maximum cell adherence was reached after 5-6 h  incubation and was 
3-10 times higher with CSF-a incubated ceils than with control eosinophils. Schisto- 
somula mortality recorded after 20 h  was enhanced to the same extent (Fig. 4). 
Eosinophils that had been preincubated with CSF-a and then washed and added 
to antibody-coated schistosomula demonstrated an increase of adherence as early as 
30-45  min after  addition of the  cells to  the  parasites  (Fig.  5).  A  similar degree  of 
adherence was reached 45-60 min later by eosinophils that had been in contact with 
CSF-a in the second culture only. This shows that the enhancing effect of CSF-a on 
cell adherence requires a minimum of 45-60 min to be detectable. 
Enhancement  of  Eosinophil Adherence  by  CSF-a  Occurs  in  the  Absence  of  Protein 
Synthesis.  Enhancement of eosinophil adherence by CSF-a occurs in the presence of 
doses ofpuromycin that totally inhibit eosinophil protein synthesis (see Materials and DESSEIN,  VADAS,  NICOLA,  METCALF,  AND  DAVID 
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FIG.  3.  (left) Enhancement by HPCM of the complement-dependent eosinophil-mediated killing 
of schistosomula. Schistosomula were  incubated with  eosinophils (>88%  pure  from donors with 
blood eosinophil counts of 4 and 9%) and various dilutions of fresh normal human serum (as source 
of complement). HPCM (1/100) was added to the culture at the beginning of the incubation period. 
Each point represents the arithmetic mean ±  SD of the schistosomula mortality observed in two 
separate experiments. 
Fro.  4.  (right)  Effect of CSF-ot on Ab-dependent eosinophil adherence to schistosomula. Schisto- 
somula were  incubated  with human eosinophils (98%  pure;  donor eosinophilia,  8  and  7%)  and 
antischistosomular serum  (¼6o or  ~  dilutions~.  CSF-a  was  added  to  the  culture  (1As0) at  the 
beginning of the  incubation  period.  Eosinophil  adherence  (two  experiments)  is recorded  as  the 
percentage ±  SD of organisms bearing >20 cells. Killing was scored after 24 h incubation. -  -  -, Ab 
1A~; --,  Ab ~o. 
TABLE  II 
Purification of Eosinophil Cytotoxicity-enhancing  Activity by Filtration through Phenyl-Sepharose and 
Sepharose G-I O0 Columns 
95 
HPCM fraction 
Percent dead schistosomula 
Eosinophils  Neutrophils 
Ab  Eosinophils  +  Ab  +  Ab 
None  6:1:3  5 ±  2  18 ±  5  7 ±  3 
Phenyl-Sepharose fractions 
a  4±  1  15±4"  70±5*  4±5 
fl  ND  8±3  20±2  6±4 
None  5 ±  3  8 ±  5  16 ±  4  8 ±  3 
G-100 (fraction 30,000 mol wt)  7 :t: 4  10 ±  3  73 ±  10  7 ±  4 
HPCM  was  fractionated  by  filtration  through  phenyl-Sepharose  and  Sephadex  G-100  columns  as 
described  in  Materials  and  Methods,  and  fractions  were  added  (¼00 dilution)  to  the culture  at  the 
beginning of the incubation period. Eosinophils (>89% pure) and neutrophils (99% pure) were obtained 
from the blood of five patients (blood eosinophil count, 2-15%). Numbers represent arithmetic means of 
duplicate determinations ±  SE obtained in six experiments (upper part of the table) and three experiments 
(lower part of the table). 
* These values differ significantly from vertically adjacent values (P <  0.0t). 96  IN  VITRO ACTIVATION OF  HUMAN BLOOD  EOSINOPHILS 
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Fro.  5.  (left) Time required for enhancement of eosinophil  adherence by CSF-a. Eosinophils  (95% 
pure from patients with blood eosinophil  counts of 6 and  12%) were incubated in MEM/FCS/D 
:t: CSF-a for 60 min, then Ab-coated schistosomula  were added to the culture, and cell adherence 
was scored at regular time intervals (3/4, 1½, and 3 h). Control eosinophils  were kept at 37°C in 
MEM/FCS/D during the preincubation period,  and their ability to adhere to Ab-coated schisto- 
somula in the presence  or absence  of CSF-a (1/100) was  tested  as above. Eosinophil adherence  is 
expressed as the percentage of schistosomula  bearing >20 cells. Each bar represents  the arithmetic 
mean of duplicate determinations "4- SD (two experiments). 
Fie.  6.  (right)  Effect  of CSF-a  on  Con  A-dependent  eosinophil  adherence  to  schistosomula. 
Eosinophils  (2  x  105  per tube)  were incubated  ½ h  at  37°C  in  MEM/FCS/D  + .CSF-a  (¼00 
dilution),  then  schistosomula  (100/tube)  and  Con  A  (100 /tg/ml)  were added  and  incubation 
forwarded at 37°C. At regular time intervals  (1, 2, 3½, and  5 h),  four tubes in each group were 
removed from the incubator and aCH3 mannoside (2 ×  10  -l M) was added to two of them. After 
gently mixing, these tubes were incubated at 37°C for a further 30 min, then eosinophil adherence 
was scored. Eosinophil  adherence is expressed as the percentage of larvae bearing >10 cells. Very 
few larvae (<5%) bore >20 cells. Each point represents the mean of duplicate determinations in two 
(1, 2, and 3a/z h) and four (5 h) separate experiments.  Bar represents  standard deviations between 
experiments.  0, Eos +  Con A; &, Eos +  Con A +  t~CH3 mannoside; C), Eos +  CSF-a +  Con A; 
A, Eos + CSF-a + Con A +  aCH3 mannoside. 
Methods).  As  is  shown  in  Table  III,  this  occurs  whether  puromycin  was  present 
during the activation period only (experiments  1 and 2) or during the whole adherence 
assay  (experiments  3  and  4).  No effect of puromycin  on the enhancement  by CSF-a 
of the  eosinophil-mediated  killing of schistosomula  was  detected  (Table  III,  experi- 
ments  1  and  2)  when  puromycin  was  added  during  a  short  activation  period. 
Enhancement  by  CSF-a  of the  eosinophil-mediated  killing  of the  larvae  was  also 
observed when puromycin  was present during the complete (20 h)  assay (experiments 
3  and  4)  but  was  less  dramatic  in  tubes  with  puromycin  than  in  tubes  without. 
Puromycin also inhibited the killing reaction in the absence of CSF-a  (experiment 5). 
This  phenomenon  has  been  reported  for  other  antibody-dependent  cell-mediated 
cytotoxieity reactions  (33)  and  might reflect the need for a  minimum  level of protein 
synthesis  for  maintenance  of the  cells  in  killing  reactions  (33)  rather  than  a  true 
requirement  for newly synthesized  proteins  for the killing process itself. 
Stage of the Killing Reaction Affected by CSF-cc  Adherence of eosinophils to antibody- 
coated  schistosomula  is a  two-step  process  (28,  34).  The  first  step  is a  temperature- 
independent  reaction  via  Fc  receptors,  whereas  the  second  step  is  a  temperature- 
dependent  reaction,  possibly involving cell degranulation  that  makes  the cell adher- 
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TABLE  III 
Effect of Puromycin on Enhancement by CSF-a of the Ab-dependent Eosinophil Adherence and Eosinophil- 
mediated Damage to Schistosomula 
Experi- 
ment 
Percent dead 
Time with agent  Percent eosinophil adherence*  schistosomula:~ 
CSF-a  Puromycin  60 min  90 min  150 min  20 h 
0  0  8  17  19 ±  2 
0  30 min  13  10  17 ±  5 
10 min  0  77  79  41 ±  6 
10 min  30 min  64  70  33 ±  7 
0  0  23  13  26  13 ±  2 
0  60 min  5  6  4  17 ±  3.5 
40 min  0  52  86  60  43 ±  7 
40 min  60 min  41  64  40  34 ±  1.5 
0  0  5  21  30  6± 2 
0  20 h  4  12  13  3 ±  2 
20 h  0  38  40  65  44 =1:2 
20 h  20 h  56  59  50  17 ±  1§ 
0  0  9  15+5 
0  20h  2  10± 3 
20 h  0  57  52 ±  5 
20 h  20 h  43  43 ±  6 
0  0  75 ±  13 
0  20 h  43 ±  5§ 
Eosinophils  were incubated in  MEM/FCS/D with or without puromycin for  10  min at  37°C,  then 
CSF-a was added at 111oo dilution. In experiment 1 and 2, cells were washed three times 10 or 40 min later 
and resuspended for a further 10-min incubation period in MEM/FCS/D ±  puromycin; then cells were 
washed again  three times, and their ability to adhere to and to kill  Ab-coated larvae was tested as 
described in Materials and Methods. In experiments 3 to 5, cells were kept  during the whole assay in 
MEM/FCS/D ±  puromycin. F_,osinophils  from four different patients (blood eosinophil count, 4-12%) 
were  used.  Eosinophil  purity  was  >90%  when  eosinophil adherence was  tested,  and  >87%  when 
eosinophil-mediated  killing was assayed  (see Materials and Methods). Puromycin concentrations were 5 
#g/ml in experiment 1, 10 #g/ml in experiments 2, 3, and 4, and 15 #g/ml in experiment 4. 
* Single  determinations in  experiments 1 and  2  and  arithmetic mean of duplicate determinations in 
experiments 3 and 4 (SD, <7%). 
:~ Arithmetic mean of duplicate determinations (experiments 1,  2,  3,  and 4)  and  arithmetic mean of 
duplicate determinations in three separate experiments (experiment 5). 
§ These values differ significantly  from vertically adjacent values (P <  0.02). 
Eosinophils that had been preincubated for 2  h  at 37°C with CSF-a  did not show 
enhanced  adherence  to  Ab-coated  schistosomula  when  the  adherence  assay  was 
performed at 4°C (Table IV). This shows that CSF-a does not affect the temperature- 
independent stage of eosinophil adherence that is mediated by Fc receptors. As soon 
as the adherence assay was warmed to 37°C, CSF-a preincubated eosinophils adhered 
much  better than  control eosinophils to Ab-coated larvae  (Table IV in experiments 
1 and 3). 
CSF-a Incubated Eosinophils Adhere Irreversibly  to Con A-coated Schistosomula.  The results 
of the above experiments show that CSF-a affects the temperature-dependent  stage of 
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TABLE  IV 
CSF-a Enhances  the Temperature-dependent Stage of Eosinophil Adherence to Ab-coated Schistosomula 
~'"  ;~xver'"  CSF-a  Adherence assay 
ment 
Schistosomula bearing* 
0-5 cells  >5 cells  >10 cells  >20 cells 
°C  h 
-  53  49  21 
37  1½ 
+  l0  90  50:~ 
-  76  24  0 
4  4 
+  79  21  0 
then 
-  44  57  36 
37  ½ 
+  0  100  78% 
ND 
ND 
0 
0 
ND 
ND 
2  -  85  15  0  0 
4  12 
+  88  11  0  0 
3  -  72  22  0.5  0 
4  14 
+  83  5  0  0 
then 
-  13  87  63  23 
37  ½ 
+  5  95  90  62~ 
Eosinophils (>96% pure) were incubated  (37°C, 2 h, 2  ×  105/tube)  in assay medium with or without 
CSF-a, then tubes were either kept at 37°C (experiment 1, first two lines) or transferred at 4°C, and 100 
schistosomula that had been coated with human antischistosomular antibodies  (dilution ~, 30  min at 
37°C) were added to each tube. Eosinophil adherence was scored after a further 1½ h at 37°C (experiment 
1, first  two lines)  or 4-14-h incubation period at  4°C. Tubes remaining at 4°C  (experiments  1 and 3) 
were then retransferred at 37°C, and eosinophil adherence was scored ½ h later. 
* Eosinophil adherence is expressed as the percentage of larvae bearing 0-five cells,  >5,  10,  or 20  cells. 
Numbers are arithmetic means of duplicate determinations, and standard deviations were <8%. 
:~ Values that differ significantly from their controls (incubations without CSF-a), P <  0.02. 
adherence irreversible. That hypothesis was tested in the Con A-dependent eosinophil 
adherence assay. Eosinophils adhere to Con A-coated schistosomula, and this adher- 
ence  is  fully reversible  by  addition  of a-methyl  mannoside  (28).  We  found  that 
adherence of eosinophils to Con A-coated schistosomula becomes irreversible when 
CSF-a  is  added  to  the  culture  (Fig.  6).  Maximum  irreversibility  of the  Con  A- 
dependent  eosinophil  adherence  was  achieved  after  5  h  incubation  with  CSF-a, 
corresponding to the period  required  for maximum adherence of CSF-a-activated 
eosinophils to  antibody-coated sehistosomula  (Fig.  4).  In  four experiments, CSF-a 
incubated eosinophils, like normal eosinophils, failed to kill Con A-coated schistosom- 
ula (data not shown). 
Discussion 
The  observation  that  eosinophils  from  eosinophilic  patients  have  an  enhanced 
helminthotoxicity (8)  suggested that the functional activity of mature blood eosino- 
phils might be regulated by factors that also control the proliferation and maturation 
of eosinophil progenitor cells. 
CSF are required for the growth and differentiation of granulocyte and macrophage 
colonies in vitro (19). They have also been shown to increase RNA (20) and protein 
synthesis (21) in mature cells and to enhance the killing of leishmania promastigote 
parasites  by  macrophages  (22).  Finally, granulocyte and  macrophage  CSF  serum DESSEIN, VADAS, NICOLA, METCALF, AND DAVID  99 
levels fluctuate sharply under conditions that  involve altered rates of polymorpho- 
nuclear cell and monoeyte production, such as in granulocyte leukemia (35)  and in 
viral (36)  and bacterial (37)  infections. This suggests that colony-stimulating factors 
could  have  the  dual  function  of regulating  granulopoiesis  and  of controlling the 
activity of mature granulocytes. 
The data  presented  here show  that  human  placental  conditioned medium  that 
contains eosinophil CSF does, in fact, significantly enhance human blood eosinophil 
helminthotoxicity. This enhancement represents a 4-10-fold increase in the eosinophil 
schistosomicidal activity and allowed eosinophils to kill Ab- or complement-coated 
larvae at Ab or complement concentrations ten times lower than the Ab or comple- 
ment  concentratons required by normal eosinophils to damage schistosomula. The 
activity that enhances eosinophil helminthotoxicity and the eosinophil colony-stimu- 
lating activity of HPCM  are eluted in the same fraction after chromatography on 
Sephadex G-100 and phenylsepharose columns, suggesting that both activities might 
be associated with the same molecule. 
The  conditions  required  for  colony  stimulation  and  for  activation  of mature 
eosinophils  are  different.  Removal  of CSF  from  bone  marrow  cultures  causes  an 
immediate cessation of granulocyte proliferation (38, 39), whereas washing eosinophils 
a few minutes after the addition of CSF-a does not prevent full activation. Moreover, 
eosinophil  activation  when  assessed  by  enhancement  of eosinophil  adherence,  in 
contrast to cell proliferation and maturation, does not require protein synthesis. This 
suggests that eosinophil CSA and the activity that enhances eosinophil helminthotox- 
icity act on eosinophil progenitors and on mature eosinophils by different mechanisms. 
We attempted to determine how CSF-a enhances the killing reaction. It was first 
observed that  CSF-a enhances antibody-dependent adherence of eosinophils to the 
larvae,  and  the  subsequent  increase  of parasite  death  was  proportional  to  this 
enhancement. Because the killing of schistosomula by eosinophils requires the attach- 
ment of the cells to the parasite tegument, it is reasonable to assume that the effect of 
CSF-a on eosinophil adherence accounts, at least partially, for the increase in killing. 
CSF-a could modify eosinophil adherence in several ways. First, as Anwar et al. 
(40)  and  Capron  et  al.  (5)  have  reported  for  eosinophil  chemotactic  factor  of 
anaphylaxis-activated eosinophils, CSF-a could increase the number of eosinophil CR 
(40) and Fc receptors (5). This is probably not the case here because the temperature- 
independent stage of eosinophil adherence that  is probably dependent only on the 
interaction  between  Fc  receptors  and  Ab  bound  to  schistosomula  (28,  34)  is  not 
enhanced by CSF-a.  Moreover, the number of Fc receptors detectable in a rosetting 
assay is less on CSF-a-activated eosinophils than on normal cells  (J.  F. Jakubowitz 
and M. H. Vadas, manuscript in preparation). 
CSF-a  does  affect, however,  the  temperature-dependent  stage  of the  eosinophil 
adherence  to  Ab-coated  larvae.  Thus,  eosinophils  incubated  with  CSF-a,  which 
adhere as normal eosinophils at 4°C, have enhanced adherence within a few minutes 
of reaching 37°C.  Eosinophil  adherence to Ab-coated schistosomula becomes irre- 
versible  at  37°C,  and  it  is  thought  that  irreversibility of eosinophil  adherence  is 
achieved during cell degranulation. This notion is supported by experiments showing 
that  eosinophil  adherence  mediated  by  ligands  (like  Con  A)  that  fail  to  trigger 
eosinophil degranulation  is reversible unless degranulating agents are added to the 
reaction (28). It is shown here that CSF-a incubated eosinophils adhere irreversibly 100  IN VITRO ACTIVATION OF HUMAN BLOOD EOSINOPHILS 
to Con-A-coated larvae, suggesting that CSF-a affects the mechanism, possibly cell 
degranulation,  that  insures irreversibility of cell attachment.  This interpretation is 
consistent with  the observation that  a  small  but  significant number of eosinophils 
adhere to schistosomula in the absence of Ab if these cells have been incubated with 
high doses of CSF-a. Normal eosinophils adhering to Con A-coated schistosomula kill 
the  parasite  when  the  calcium  ionophore A23187  is  added  (28),  whereas  CSF-a- 
activated eosinophils do not.  This suggests  that  irreversibility of cell adherence is 
achieved by mechanism(s) that do not necessarily damage the larvae. 
In conclusion, this study suggests that poietic molecules like eosinophil CSF could 
be the factors that enhance cytotoxicity of blood eosinophils in eosinophilic patients. 
CSF-a effects on the cell degranulation-associated events that insure irreversibility of 
eosinophil  adherence  suggest  that  these  factors  could  also  be  responsible  for  the 
abnormal tendency of eosinophils to degranulate in the blood of these patients  (12, 
13). A more definitive demonstration of the involvement of eosinophil CSF-like factors 
in  the  regulation  of blood eosinophil  functions would  require, however, a  greater 
purification  of eosinophil  CSF  and  a  more  definite  demonstration  of its  role  in 
eosinopoiesis in vivo. 
Summary 
Purified human blood eosinophils, when incubated in human placental conditioned 
medium  (a  source of colony-stimulating factors  [CSF])  demonstrate  an  enhanced 
ability to damage antibody- or complement-coated schistosomula. This enhancement 
represents a 4- to 10-fold increase of eosinophil schistosomicidal ability and a  10-fold 
lowering of the threshold for antibody or complement required in the killing reaction. 
The activity that enhances eosinophil cytotoxicity and the eosinophil colony-stimu- 
lating activity in the placental conditioned medium are eluted in the same fraction 
(CSF-a)  after chromatography on Sephadex G-100 and phenyl-Sepharose columns, 
suggesting that these two activities might be associated with the same molecule. 
CSF-a enhances the adherence step of the killing reaction: antibody-coated larvae 
were frequently found covered by several layers of eosinophils in  tubes containing 
CSF-a.  Such a  degree of adherence was rarely seen in control tubes lacking CSF-a. 
This enhancement of the eosinophil adherence is detectable 45-60 rain after addition 
of CSF-a to the culture. It is not affected by washing the cells after a  short time of 
preincubation with CSF-a, and it occurs in the absence of protein synthesis, whereas 
colony-stimulating activity requires continuous  protein  synthesis  and  ceases  when 
CSF is removed from the culture. Finally, CSF-a enhances the temperature-dependent 
reaction that insures the irreversibility of eosinophil attachment to schistosomula. 
These observations suggest that eosinopoietic factors could be responsible for some 
of the modified properties of blood eosinophils in eosinophilic individuals. 
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